{"url_path":"/sec/lab/8-k/2026-06-03/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1162194/0001193125-26-255403-index.html","accession_number":"0001193125-26-255403","cik":"0001162194","ticker":"LAB","issuer_name":"STANDARD BIOTOOLS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1162194/0001193125-26-255403-index.html","primary_entity_key":"0001162194","primary_entity_name":"STANDARD BIOTOOLS INC."},"word_count":218,"has_tables":true,"body_markdown":"Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n \n\nOn May 29, 2026, the Human Capital Committee of the Board of Directors of Standard BioTools Inc. (the “Company”) approved a grant of 500,000 restricted stock units for Sean Mackay, Chief Business Officer of the Company, under the Company’s 2026 Equity Incentive Plan (the “2026 Plan”), effective as of June 20, 2026 (the “RSU Award”). Subject to Mr. Mackay continuing to provide services to the Company through the applicable vesting dates, 40% of the RSU Award will vest on June 20, 2027, and the remaining 60% of the RSU Award will vest on June 20, 2028.\n\n \n\nThe RSU Award is subject to the terms and conditions of the 2026 Plan and the applicable RSU Award agreement thereunder. The RSU Award is also subject to the provisions of the Company’s 2026 Change of Control and Severance Plan under which Mr. Mackay participates, and his Participation Agreement thereunder.\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nDate:\n\n \n\nJune 3, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nSTANDARD BIOTOOLS INC.\n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n \n\n/s/ Alex Kim\n\n \n\nName:\n\n \n\nAlex Kim\n\n \n\nTitle:\n\n \n\nChief Financial Officer"}